The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed

Vitamin D can support not only bone health, but also insulin secretion, glucose metabolism, and cell sensitivity to its action
Doctronic offers AI-powered consultations that can synthesize the latest medical knowledge to provide personalized care
But "nutrient density" is a something that has very low consumer interest or understanding, and hence most GLP-1 products focus on protein and fibre, which consumers do understand
at 1-833-Wegovy-1 Marketed by: Novo Nordisk Inc